Who makes Lipovirtide 60mg?

Lipovirtide 60mg is developed by Shanxi Kangbao Biological Product Co., Ltd..

What development phase is Lipovirtide 60mg in?

Lipovirtide 60mg is in Phase 2.

Last reviewed 2026-04-20 · How we verify

Lipovirtide 60mg

Shanxi Kangbao Biological Product Co., Ltd. · Phase 2 active Small molecule Quality 0/100

At a glance

Generic name	Lipovirtide 60mg
Also known as	3TC, TDF
Sponsor	Shanxi Kangbao Biological Product Co., Ltd.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Assess the Effectiveness and Safety of Lipovirtide Combined With Nucleoside Drugs in HIV-infected Patients. (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Lipovirtide 60mg CI brief — competitive landscape report
Lipovirtide 60mg updates RSS · CI watch RSS
Shanxi Kangbao Biological Product Co., Ltd. portfolio CI